Flag of the European Union EU Clinical Trials Register Help

Clinical trials for COPD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    688 result(s) found for: COPD. Displaying page 7 of 35.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2004-004442-40 Sponsor Protocol Number: BY217/M2-114 Start Date*: 2005-03-21
    Sponsor Name:ALTANA Pharma AG
    Full Title: 500µg roflumilast once daily in combination with 50µg salmeterol twice daily versus 50µg salmeterol twice daily alone over 52 weeks in patients with COPD.
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    5.1 10010952 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002441-18 Sponsor Protocol Number: D6582C00001 Start Date*: 2022-10-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa Randomised, Double-Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Ongoing) NL (Completed) IT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001744-11 Sponsor Protocol Number: PT003019-01 Start Date*: 2016-10-31
    Sponsor Name:Pearl Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and...
    Medical condition: Moderate to severe Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015472 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004420-11 Sponsor Protocol Number: S55829 Start Date*: 2014-04-29
    Sponsor Name:KU Leuven - UZ Leuven
    Full Title: Azithromycin for acute COPD exacerbations with hospitalisation: the BACE trial
    Medical condition: Acute COPD exacerbations with hospitalisation.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    18.0 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000187-25 Sponsor Protocol Number: AC4108123 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled dose...
    Medical condition: Chronic Obstructive Pumonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001743-36 Sponsor Protocol Number: PT003018-00 Start Date*: 2015-12-01
    Sponsor Name:Pearl Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volu...
    Medical condition: Moderate to severe Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004031-31 Sponsor Protocol Number: RVH006 Start Date*: 2011-11-15
    Sponsor Name:RespiVert Ltd
    Full Title: A randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of treatment with repeat doses of inhaled RV568 in patients with COPD.
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003014-12 Sponsor Protocol Number: COPERNICOS_JUJCPR Start Date*: 2021-03-19
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD - Eosinophil-guided Reduction of Inhaled COrticoSteroids (COPERnICOS)
    Medical condition: Clinicaltrial on eosinophil-guided time-updated person-specific reduction of inhaled corticosteroid therapy and prophylactic azithromycin therapy in patients with severe or very severe chronic obst...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001168-28 Sponsor Protocol Number: D5899C00001 Start Date*: 2005-01-04
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-month, double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2x160/4.5μg bid and 2x80/4.5 μg bid compared to Formoterol Turbuhaler 2x...
    Medical condition: This is an application for a phase III study to be conducted in COPD patients.
    Disease: Version SOC Term Classification Code Term Level
    10010952
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) IS (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001840-33 Sponsor Protocol Number: 205.389 Start Date*: 2007-11-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD patients (a randomised, double-blind, double-dummy, parallel group, o...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) FI (Completed) GB (Completed) AT (Completed) CZ (Completed) DK (Completed) PT (Completed) LV (Completed) ES (Completed) NL (Completed) SI (Completed) FR (Completed) BE (Completed) DE (Completed) IT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-001953-28 Sponsor Protocol Number: EFC15804 Start Date*: 2019-07-01
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstr...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed) FI (Completed) CZ (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-002563-23 Sponsor Protocol Number: CD-RI-MEDI8968-1103 Start Date*: 2012-03-15
    Sponsor Name:MedImmune Limited
    Full Title: A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LV (Completed) CZ (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004548-44 Sponsor Protocol Number: 200820 Start Date*: 2014-05-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Dai...
    Medical condition: Chronic Obstructive Pulmonary Disease COPD
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-010669-22 Sponsor Protocol Number: 1237.6 Start Date*: 2011-09-19
    Sponsor Name: [...]
    1.
    2. Boehringer Ingelheim Norway KS
    Full Title: A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium plus olodaterol fixed dose combination (2.5 μg / ...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) ES (Completed) SK (Completed) BE (Completed) DE (Completed) HU (Completed) IE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006173-33 Sponsor Protocol Number: ALMED-07-C3-009 Start Date*: 2009-10-09
    Sponsor Name:Air Liquide
    Full Title: An international phase III randomised trial comparing in severe Exacerbations of Chronic obstructive pulmonary disease the efficacy of Helium/Oxygen versus Air/Oxygen administered during spontaneo...
    Medical condition: Patients eligible for this study are critically ill patients with COPD admitted in ICU for an exacerbation of their chronic disease with hypercapnic acute respiratory failure.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended) DE (Completed) IT (Ongoing) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001063-43 Sponsor Protocol Number: 11/0078 Start Date*: 2011-09-09
    Sponsor Name:University College London (UCL)
    Full Title: A Phase III single-blind, randomised, placebo controlled trial of long term therapy in patients with stable COPD using Moxifloxacin, Azithromycin, and Doxycycline: a Bayesian decision analysis, inc...
    Medical condition: COPD- Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002340-40 Sponsor Protocol Number: A9111004 Start Date*: 2014-10-16
    Sponsor Name:Pfizer Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled 2-Way Crossover Study to Evaluate the Efficacy, Safety and Tolerability of PF-03715455 Administered Twice Daily By Inhalation for 4 Weeks in Subjects ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004807-37 Sponsor Protocol Number: B2C111045 Start Date*: 2008-03-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD
    Medical condition: Chronic Pulmonary obstructive Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) DK (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003879-29 Sponsor Protocol Number: 1237.49 Start Date*: 2015-12-30
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A 4-week, randomised, double-blind, parallel group study to evaluate the efficacy and safety of tiotropium + olodaterol fixed dose combination (5/5 µg) delivered by the Respimat® inhaler versus the...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SI (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004473-41 Sponsor Protocol Number: 2016RC22 Start Date*: 2017-03-21
    Sponsor Name:University of Dundee and NHS Tayside
    Full Title: INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation with Tiotropium and Olodaterol (INCOGNITO trial)
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015472 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 02 04:46:40 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA